Last reviewed · How we verify
Oxaliplatin intra-arteriel
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, delivered directly into the hepatic artery to maximize local concentration in liver tumors.
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, delivered directly into the hepatic artery to maximize local concentration in liver tumors. Used for Colorectal cancer with hepatic metastases (intra-arterial administration).
At a glance
| Generic name | Oxaliplatin intra-arteriel |
|---|---|
| Also known as | Oxaliplatin IA |
| Sponsor | Federation Francophone de Cancerologie Digestive |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA (forms crosslinks) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin is a third-generation platinum compound that binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. When administered intra-arterially, it achieves high local drug concentrations in hepatic tumors while reducing systemic exposure. This regional delivery approach is designed to improve efficacy against colorectal cancer liver metastases while potentially reducing systemic toxicity.
Approved indications
- Colorectal cancer with hepatic metastases (intra-arterial administration)
Common side effects
- Peripheral neuropathy
- Nausea and vomiting
- Myelosuppression
- Hepatotoxicity
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: